Finance

Lists
GSK:NYSE
GSK plc
47,02 US$
+0,90%
(+0,42) 1D
46,28 US$
-1,57% (-0,74)
Pre-market
Closed: 7 ოქტ, 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GSK...
Open
46,92 US$
High
47,40 US$
Low
46,69 US$
Mkt. cap
95,26 მლრდ.
Avg. vol.
3,41 მლნ.
Volume
41,84 ათ.
Dividend
3,86%
Quarterly dividend
0,45 US$
Ex-dividend date
13 აგვ. 2026
P/E ratio
15,01
52-wk high
61,70 US$
52-wk low
42,84 US$
EPS
3,13 US$
Beta
0,25
Shares outstanding
2,02 მლრდ.
No. of employees
67 ათ.
Open
46,92 US$
High
47,40 US$
Low
46,69 US$
Mkt. cap
95,26 მლრდ.
Avg. vol.
3,41 მლნ.
Volume
41,84 ათ.
Dividend
3,86%
Quarterly dividend
0,45 US$
Ex-dividend date
13 აგვ. 2026
P/E ratio
15,01
52-wk high
61,70 US$
52-wk low
42,84 US$
EPS
3,13 US$
Beta
0,25
Shares outstanding
2,02 მლრდ.
No. of employees
67 ათ.
News stories
From web sources and news partners
Analytics Insight
Analytics Insight
·
2 საათის წინ
AstraZeneca vs GSK: Comparing Two UK Stocks in AI-Driven Healthcare
JournalArta
JournalArta
·
8 საათის წინ
Momentum Weakens, GSK Stock Gains 1.42%: What to Know
AD HOC NEWS
AD HOC NEWS
·
23 საათის წინ
GSK stock adds a liver candidate to its pipeline
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOემა უოლმსლი | ემა უოლმსლი
Employees66,8 ათ.
Founded27 დეკ. 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com
Analyst ratings
Based on 2 analysts giving stock ratings to GSK in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for GSK in the last 3 months.
Highest
Current 47,02 US$
70,00 US$ (+48,87%)
Average
65,00 US$ (+38,24%)
Lowest
60,00 US$ (+27,61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Berenberg Bank
Buy
Upgraded
60,00 US$
+27,6%
09/15/2026
Steve Scala
TD Cowen
Hold
Maintained
70,00 US$
+48,9%
08/03/2026
Jasper Hellweg
Argus Research
Buy
Maintained
-
-
06/08/2026
Michael Leuchten
Jefferies
Buy
Maintained
67,10 US$
+42,7%
05/29/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
01/29/2026
Last report
28 ივლ. 2026
Fiscal period
Q2 2026
EPS / Est. (GBP)
1,01 £ / 0,48 £
+110,86%beat
Revenue / Est. (GBP)
8,41 მლრდ. / 8,32 მლრდ.
+1,03%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
8,55 მლრდ.
8,62 მლრდ.
7,63 მლრდ.
8,41 მლრდ.
Cost of goods sold
2,24 მლრდ.
2,62 მლრდ.
1,87 მლრდ.
2,07 მლრდ.
Cost of revenue
2,24 მლრდ.
2,62 მლრდ.
1,87 მლრდ.
2,07 მლრდ.
Research and development expenses
1,58 მლრდ.
2,14 მლრდ.
1,52 მლრდ.
1,75 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,16 მლრდ.
2,67 მლრდ.
2,08 მლრდ.
2,19 მლრდ.
Operating expense
3,23 მლრდ.
4,37 მლრდ.
2,99 მლრდ.
3,74 მლრდ.
Total operating expenses
5,46 მლრდ.
6,99 მლრდ.
4,86 მლრდ.
5,81 მლრდ.
Operating income
3,08 მლრდ.
1,63 მლრდ.
2,77 მლრდ.
2,60 მლრდ.
Other non operating income
-
-21,00 მლნ.
-
-
EBT including unusual items
2,46 მლრდ.
950,00 მლნ.
2,14 მლრდ.
354,00 მლნ.
EBT excluding unusual items
2,94 მლრდ.
1,48 მლრდ.
2,62 მლრდ.
2,48 მლრდ.
Income tax expense
312,00 მლნ.
223,00 მლნ.
305,00 მლნ.
-199,00 მლნ.
Effective tax rate
12,70%
23,47%
14,23%
-56,21%
Other operating expenses
-511,00 მლნ.
-434,00 მლნ.
-615,00 მლნ.
-204,00 მლნ.
Net income
2,01 მლრდ.
636,00 მლნ.
1,74 მლრდ.
435,00 მლნ.
Net profit margin
23,55%
7,38%
22,77%
5,17%
Earnings per share
0,55
-
-
-
Interest and investment income
26,00 მლნ.
17,00 მლნ.
22,00 მლნ.
58,00 მლნ.
Interest expense
-167,00 მლნ.
-145,00 მლნ.
-167,00 მლნ.
-182,00 მლნ.
Net interest expenses
-141,00 მლნ.
-128,00 მლნ.
-145,00 მლნ.
-124,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
3,82 მლრდ.
2,69 მლრდ.
3,23 მლრდ.
2,82 მლრდ.
Gain or loss from assets sale
-
-40,00 მლნ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები